Guidance for Industry (GFI): Electronic Drug Product Reporting for Human Drug Compounding Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act
ICR 201610-0910-005
OMB: 0910-0827
Federal Form Document
⚠️ Notice: This information collection may be outdated. More recent filings for OMB 0910-0827 can be found here:
Guidance for Industry (GFI):
Electronic Drug Product Reporting for Human Drug Compounding
Outsourcing Facilities Under Section 503B of the Federal Food,
Drug, and Cosmetic Act
New
collection (Request for a new OMB Control Number)
After an entity has elected to
register as an outsourcing facility, it must report information
identifying the drugs compounded at the facility in Structured
Product Labeling format using FDA’s electronic submissions system.
The final guidance addresses new provisions in the Federal Food,
Drug, and Cosmetic Act added by the Drug Quality and Security Act
and updates reporting instructions for drug compounders that choose
to register as outsourcing facilities.
US Code:
21
USC 353b Name of Law: Federal Food, Drug, and Cosmetic Act;
Outsourcing Facilities
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.